Introduction
Tagrisso is a branded prescription medicine containing osimertinib as its active ingredient. It belongs to a class of targeted anticancer medicines called epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. The medicine is used in specific treatment settings involving EGFR-mutated non-small cell lung cancer (NSCLC).
AstraZeneca is the company associated with the reference Tagrisso brand. However, the company associated with a brand should not automatically be assumed to be the physical manufacturer, importer, distributor or marketing authorization holder for every product presentation in every country. These responsibilities may differ according to the product, market and supply arrangement.
This page explains the relationship between Tagrisso, osimertinib and the company associated with the reference brand. It also discusses the importance of identifying the responsible pharmaceutical organizations, checking product labeling and obtaining prescription medicines through legitimate supply channels.
What Is Tagrisso?
Tagrisso is the brand name for osimertinib, an oral targeted anticancer medicine. Its active ingredient inhibits certain mutated forms of EGFR, a receptor involved in signaling pathways that regulate cell growth and survival.
In some lung cancers, genetic changes cause EGFR signaling to become abnormally active. Osimertinib targets particular altered forms of the receptor, including specified activating mutations and the T790M resistance mutation.
Depending on the applicable authorization and the patient’s clinical circumstances, Tagrisso may be used after surgery, following certain chemoradiation treatment, or for locally advanced or metastatic EGFR-mutated NSCLC. In selected cases, it may be prescribed with pemetrexed and platinum-based chemotherapy.
The medicine requires a prescription and appropriate oncology supervision. Its use depends on the relevant molecular test results, cancer stage, previous treatment and clinical assessment.
Company Associated With the Reference Tagrisso Brand
AstraZeneca is associated with the reference Tagrisso brand. This identifies the company associated with the branded medicine, but it does not establish the manufacturing history of an individual package.
Pharmaceutical products may pass through several stages before reaching a patient. These stages can involve development, manufacturing, quality control, packaging, authorization, importation and distribution. Different organizations may be responsible for different parts of this process.
For this reason, the information printed on a particular product’s packaging should be reviewed alongside the official product documentation applicable to the relevant country. The name of a responsible company should not be inferred solely from the brand name.
Manufacturer, Marketing Authorization Holder and Distributor
Understanding pharmaceutical company roles helps readers interpret product labeling accurately.
Manufacturer
The manufacturer is the organization responsible for specified manufacturing activities. Depending on the arrangement, different facilities or companies may be responsible for production, testing or packaging.
A company associated with a brand does not necessarily manufacture every batch at a single facility. Manufacturing arrangements should be confirmed through the actual product documentation rather than assumed.
Marketing Authorization Holder
The marketing authorization holder is the organization responsible for the relevant marketing authorization in a particular jurisdiction. Its responsibilities and regulatory obligations are defined by that jurisdiction’s rules.
The authorization holder may be different from the physical manufacturing company. Its identity should therefore be checked against the applicable official product information.
Importer and Distributor
An importer may be responsible for bringing a medicine into a country, while a distributor may handle its supply through an authorized distribution network.
These organizations may be identified on local packaging or associated documentation. Their roles can vary between markets, and their presence does not independently establish that a product is authentic.
Why These Distinctions Matter
Confusing these roles can lead to inaccurate assumptions about where a medicine was manufactured, who is responsible for its authorization, or whether a particular package is approved for a specific market.
When verifying Tagrisso, patients and healthcare professionals should rely on the actual packaging, relevant official records and advice from a pharmacist or other qualified professional.
Tagrisso 80 mg Product Information
The featured product on this website is Tagrisso 80 mg, an oral tablet containing 80 mg of osimertinib.
| Product detail | Information |
|---|---|
| Brand name | Tagrisso |
| Generic name | Osimertinib |
| Active ingredient | Osimertinib |
| Featured strength | 80 mg |
| Dosage form | Oral tablet |
| Medicine class | EGFR tyrosine kinase inhibitor |
| Therapeutic category | Targeted anticancer medicine |
| Company associated with the reference brand | AstraZeneca |
| Main treatment area | Selected EGFR-mutated NSCLC |
Other strengths or product presentations may be available in particular markets. Product availability and authorization should be confirmed against current official documentation for the relevant country.
The 80 mg strength identifies the amount of active ingredient in each tablet. It does not independently determine the correct regimen for every patient. The treating oncologist must determine the appropriate dose and schedule according to the indication, prescribing information and individual clinical circumstances.
Why Manufacturer Information Matters
Manufacturer and company information can help establish a medicine’s identity and clarify which organization is responsible for particular product activities. It may also support the investigation of quality concerns, labeling discrepancies or possible product recalls.
Correct identification is particularly important for prescription anticancer medicines. A product with an uncertain origin may have been stored incorrectly, mislabeled, repackaged improperly or supplied outside legitimate distribution channels.
Patients should not assume that two packages are equivalent simply because they carry similar names or contain the same stated strength. The active ingredient, dosage form, labeling, expiry date and authorized supply arrangements should be considered together.
If a package lists a company name that differs from information found on another product, the difference should be checked rather than automatically treated as evidence of a counterfeit medicine. Different authorized presentations can have different responsible entities. A pharmacist or relevant regulatory authority can help clarify the discrepancy.
Checking Tagrisso Packaging and Labeling
Before using a prescribed medicine, patients and caregivers should review the available packaging information carefully.
Important details include:
- Brand name: Confirm that the package identifies the prescribed product as Tagrisso.
- Active ingredient: Check that osimertinib is stated as the active ingredient.
- Strength: Confirm that the product strength matches the prescription.
- Dosage form: Check that the product is the expected oral tablet.
- Company information: Review the manufacturer and other responsible organizations identified on the packaging.
- Batch or lot number: Confirm that the identifying details are present where required.
- Expiry date: Ensure that the product has not expired.
- Packaging condition: Check for damage, broken seals or signs of tampering.
- Label consistency: Review whether the information is complete and consistent with the applicable product documentation.
These checks are useful but cannot independently authenticate a medicine. Counterfeit or improperly supplied products may imitate legitimate packaging.
If a product’s identity, origin or condition is uncertain, patients should ask a pharmacist or authorized supplier to assess it before use.
The Importance of Legitimate Medicine Sources
Prescription medicines should be obtained through legitimate supply channels that comply with local laws and prescription requirements.
Unregulated supply can create risks involving incorrect ingredients, inadequate quality controls, improper storage, expired products or unreliable labeling. These risks are particularly important for cancer medicines, where the correct medicine, strength and treatment schedule are essential.
Patients should avoid products offered without appropriate prescription requirements or accompanied by unsupported claims of guaranteed effectiveness. A low price, familiar-looking package or seller assurance is not sufficient evidence of authenticity.
If access to a prescribed medicine is difficult, patients should discuss the situation with their oncology team or pharmacist. They may be able to explain lawful supply options and appropriate next steps.
Manufacturer Information and Patient Safety
The company associated with a medicine does not determine whether the treatment is suitable for a particular patient. Tagrisso can cause serious adverse reactions, including interstitial lung disease or pneumonitis, QT prolongation, cardiomyopathy, keratitis and aplastic anemia.
Patients should use the medicine only under appropriate medical supervision and follow the official prescribing instructions. New or worsening breathing difficulties, fainting, an irregular heartbeat, significant chest symptoms or serious visual changes require prompt medical assessment.
Questions about adverse effects, possible interactions, treatment interruptions or dose adjustments should be directed to the treating oncology team.
Conclusion
Tagrisso is the reference brand associated with AstraZeneca and contains osimertinib. The product featured on this website is the 80 mg oral tablet. Specific manufacturing, authorization, importation and distribution details must be established from the actual product packaging and relevant official records.
This website provides educational information about Tagrisso. It does not claim to manufacture, authorize, distribute or authenticate individual medicine packages.
Medical disclaimer: This content is for educational purposes only and does not replace professional medical advice, diagnosis, treatment or official prescribing information. Always consult a qualified healthcare professional about prescription medicines and product-related concerns.